The FDA would regain some of its ability to oversee diagnostic tests developed in a single laboratory under a bipartisan measure introduced Thursday.
The bill, known as the VALID Act, aims to resolve an ongoing debate about the agency’s authority over lab-developed diagnostics, an uncertainty the Trump administration exacerbated last summer when it allowed more tests to hit the market without FDA review.
Reps. Larry Bucshon (R-Ind.) and Diana DeGette (D-Colo.) reintroduced the measure, which stands for “verifying accurate leading-edge in vitro clinical test development.” It’s largely similar to the one the House members introduced last year just before ...